735 related articles for article (PubMed ID: 25385007)
1. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
[TBL] [Abstract][Full Text] [Related]
2. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles--a preliminary report.
Haas J; Zilberberg E; Dar S; Kedem A; Machtinger R; Orvieto R
J Ovarian Res; 2014 Aug; 7():77. PubMed ID: 25296696
[TBL] [Abstract][Full Text] [Related]
4. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
5. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
[TBL] [Abstract][Full Text] [Related]
6. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
[TBL] [Abstract][Full Text] [Related]
7. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
[TBL] [Abstract][Full Text] [Related]
8. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
9. Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study.
Haas J; Zilberberg E; Nahum R; Mor Sason A; Hourvitz A; Gat I; Orvieto R
Gynecol Endocrinol; 2019 Jul; 35(7):628-630. PubMed ID: 30810400
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
Haas J; Bassil R; Samara N; Zilberberg E; Mehta C; Orvieto R; Casper RF
Hum Reprod; 2020 Jul; 35(7):1648-1654. PubMed ID: 32563188
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
12. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
[TBL] [Abstract][Full Text] [Related]
13. GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial.
Yan MH; Cao JX; Hou JW; Jiang WJ; Wang DD; Sun ZG; Song JY
Front Endocrinol (Lausanne); 2022; 13():831859. PubMed ID: 35418945
[TBL] [Abstract][Full Text] [Related]
14. Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study.
Haas J; Ophir L; Barzilay E; Machtinger R; Yung Y; Orvieto R; Hourvitz A
Fertil Steril; 2016 Sep; 106(3):653-659.e1. PubMed ID: 27341989
[TBL] [Abstract][Full Text] [Related]
15. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
16. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
19. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
20. Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.
Abbara A; Hunjan T; Ho VNA; Clarke SA; Comninos AN; Izzi-Engbeaya C; Ho TM; Trew GH; Hramyka A; Kelsey T; Salim R; Humaidan P; Vuong LN; Dhillo WS
Front Endocrinol (Lausanne); 2020; 11():537205. PubMed ID: 33123084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
